While PD-1-targeting immunotherapy has achieved significant success in melanoma, endometrial, lung, and kidney cancers [10], common immunotherapy targets like PD-1 and CTLA-4 have been less effective in ovarian cancer. This evidence concerns the gene PDCD1 and melanoma.